Log In
BCIQ
Print this Print this
 

DaunoXome, daunorubicin

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionDaunoXome liposomal daunorubicin
Molecular Target DNA
Mechanism of ActionTopoisomerase II inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/05/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today